Ekaterina Nikolaevskaya

Prior to joining Accelerated Pharma, Ms. Nikolaevskaya served as executive and operational director at Panacela Labs, where 5 innovative research projects were developed from hit to lead and the top asset has now Phase I. She has over 15 years of experience in drug research and development. Through her executive roles at ClinStar, she oversaw the clinical development of multicenter clinical Phases II-IV studies for different Bristol-Myers Squibb drug candidates. Her work contributed to several regulatory approvals including Glucophage, Avapro, Plavix, Abilify, Yervoy, and Baraclude. She was also the co-founder of Prudential and FNP Clinical, CROs specialized in early clinical development and served there as its Chief Operating Officer. Prior to joining the industry, she spent a decade in genetic research.